The Tumor Targeting Performance of Anti-CD166 Probody Drug Conjugate CX-2009 and its Parental Derivatives as Monitored by 89Zr-immuno-PET in Xenograft Bearing Mice

Chomet M, Schreurs M, Nguyen M, et al. Theranostics. 2020; 10(13): 5815-5828. doi:10.7150/thno.44334.